Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.
暂无分享,去创建一个
I. Komuro | T. Ogura | S. Kushida | H. Nakaya
[1] I. Komuro,et al. Efficacy of nifekalant hydrochloride on the treatment of life-threatening ventricular tachyarrhythmias during reperfusion for acute myocardial infarction , 2001, Cardiovascular Drugs and Therapy.
[2] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[3] M. Jiang,et al. Use-dependent 'agonist' effect of azimilide on the HERG channel. , 1999, The Journal of pharmacology and experimental therapeutics.
[4] M. Keating,et al. MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.
[5] G. Beatch,et al. Kinetics of rate‐dependent shortening of action potential duration in guinea‐pig ventricle; effects of IK1 and IKr blockade , 1999, British journal of pharmacology.
[6] H. Nakaya,et al. Electropharmacology of Nifekalant, a New Class III Antiarrhythmic Drug , 1998 .
[7] M. Omata,et al. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? , 1997, Journal of the American College of Cardiology.
[8] K. Kamiya,et al. Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. , 1996, Cardiovascular research.
[9] Christopher Miller. The inconstancy of the human heart , 1996, Nature.
[10] Gary Yellen,et al. The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.
[11] G. Robertson,et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.
[12] I. Hisatome,et al. A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. , 1995, The Journal of pharmacology and experimental therapeutics.
[13] Y. Nakaya,et al. Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551. , 1995, Pharmacology & toxicology.
[14] Y. Hara,et al. Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms. , 1995, Circulation.
[15] A. Camm,et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). , 1995, The American journal of cardiology.
[16] A. Hirasawa,et al. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. , 1995, Japanese journal of pharmacology.
[17] L. Chi,et al. MS‐551 Protects Against Ventricular Fibrillation in a Chronic Canine Model of Sudden Cardiac Death , 1995, Journal of cardiovascular pharmacology.
[18] K. Umemura,et al. Effects of MS-551, a New Class III Antiarrhythmic Drug, on Programmed Stimulation-Induced Ventricular Arrhythmias, Electrophysiology, and Hemodynamics in a Canine Myocardial Infarction Model , 1994, Journal of cardiovascular pharmacology.
[19] L. Chi,et al. Antiarrhythmic Agent, MS‐551, Protects Against Pinacidil + Hypoxia‐Induced Ventricular Fibrillation in Langendorff‐Perfused Rabbit Isolated Heart , 1994, Journal of cardiovascular pharmacology.
[20] E. Carmeliet. Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. , 1993, Circulation research.
[21] J. Mason. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. , 1993, The New England journal of medicine.
[22] H. Nakaya,et al. Effects of MS‐551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes , 1993, British journal of pharmacology.
[23] D. Snyders,et al. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.
[24] B F Hoffman,et al. Action Potential Prolongation and Induction of Abnormal Automaticity by Low Quinidine Concentrations in Canine Purkinje Fibers Relationship to Potassium and Cycle Length , 1985, Circulation research.
[25] S. Yasuda,et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. , 2001, Japanese circulation journal.
[26] Baofeng Yang,et al. Transmembrane I Ca contributes to rate-dependent changes of action potentials in human ventricular myocytes. , 1999, American journal of physiology. Heart and circulatory physiology.
[27] M. Ishii,et al. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. , 1992, Japanese journal of pharmacology.